Loading...

Novo Nordisk A/S

NONOFPNK
HealthcareBiotechnology
$70.69
$1.49(2.15%)

Novo Nordisk A/S NONOF Peers

See (NONOF) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NONOF$70.69+2.15%313.8B19.80$3.57+2.35%
CSLLY$79.70+0.06%154.4B29.30$2.72+1.67%
CMXHF$152.17-8.23%73.7B27.92$5.45+1.82%
BBIXF$0.05+50900.00%44B-5.10-$0.01N/A
UCBJY$90.86+2.91%35.3B28.94$3.14+0.87%
ARGNF$562.00N/A34.3B34.25$16.41N/A
UCBJF$179.39+2.07%34.1B28.75$6.24+0.88%
ODTC$22,005.00+29.44%24.1B-0.08-$268,995.00N/A
WXIBF$3.20+6.67%13B29.09$0.11N/A
IVBXF$7.81-1.74%12.9B-780.64-$0.01N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NONOF vs CSLLY Comparison

NONOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NONOF stands at 313.8B. In comparison, CSLLY has a market cap of 154.4B. Regarding current trading prices, NONOF is priced at $70.69, while CSLLY trades at $79.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NONOF currently has a P/E ratio of 19.80, whereas CSLLY's P/E ratio is 29.30. In terms of profitability, NONOF's ROE is +0.81%, compared to CSLLY's ROE of +0.15%. Regarding short-term risk, NONOF is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for NONOF.

Stock Price Comparison

Loading...

Frequently Asked Questions